



## NEW PRESIDENT AND CEO JOINS BIOLEX, INC.

**PITTSBORO, NC, JULY 12, 2001** - Biolex, Inc., a biotechnology company with a proprietary plant-based protein development and manufacturing technology announced today the appointment of Mr. Jan P. Turek as the Company's new President and Chief Executive Officer. Mr. Turek was previously Senior Vice President and General Manager, Biological Products Business Unit, Bayer Corporation, Pharmaceutical Division in Raleigh, NC, a \$1 billion biopharmaceutical business unit.

Gabriel R. Cipau, Ph.D., Biolex, Inc.'s former President and CEO and instrumental in the growth, development and strategic direction of the company, will remain with Biolex on the company's Board of Directors. Commenting on the appointment, "We are thrilled to have Jan join us at Biolex," said Cipau. "Jan has proven global experience in the biopharmaceutical industry, bringing key biotechnology products from research to market. The appointment of Jan will serve the company well as we continue to develop and introduce our patented technology to a growing market."

Mr. Turek spent over 13 years with Bayer Corporation in increasingly responsible management positions where he was most recently Senior Vice President and General Manager, Biological Products Business Unit in Raleigh, NC where he oversaw 3000 people. He started this Business Unit, establishing its vision, objectives and strategic direction. Previously, Mr. Turek was Vice President, International Sales and Marketing, Biological Products. Prior to this he was Head of Cardiovascular and Central Nervous System (CNS) Products, International Strategic Marketing for Bayer AG, Health Care Sector, Pharmaceutical Division, Leverkusen, Germany.

Earlier posts include marketing management positions with Miles Canada, Inc., Toronto, Canada (Miles name eventually changed to Bayer), and with Mead Johnson Canada (Division of Bristol Myers). His biopharmaceutical career began in hospital sales with Sandoz Canada Ltd covering the Toronto and Montreal territories.

more ...





## **NEW PRESIDENT AND CEO JOINS BIOLEX, INC.**

Mr. Turek received his BS in Biochemistry from McGill University, Montreal, PQ, Canada. He was formerly Chairman of the International Plasma Products Industry Association (IPPIA).

"I am excited about my new position with Biolex," said Turek. "Biolex's patented, plant-based Lemna System<sup>®</sup> technology is at the leading-edge of the recombinant protein business and is the future of biotechnology. I look forward to applying my global biopharmaceutical experience to help take Biolex's technology to the next level, to identify new opportunities to grow this exciting business."

Biolex, Inc. is a biotechnology company devoted to discovering, developing and commercializing proteins derived from proprietary plant-based technology for the development of human and animal therapeutics, and other biotechnology applications. The company's headquarters and laboratory facility are based in Pittsboro, N.C., strategically located near Research Triangle Park. Visit the company's new web site at [www.biolex.com](http://www.biolex.com).

CONTACT: Jan P. Turek, President and CEO, Biolex, Inc. 919.542.9901 or Lisa A. Wilder, President, Wilder Communications, Inc., 919.349.3357

###

